Fusiomica drug discovery

Our lead binder targets a marker shared by several cancers

We’re developing our own binder for cancer imaging and treatment. We use AI to shorten design rounds. Then we plan a small PET study to see whether the binder reaches tumours in people.

What is theranostics?

Theranostics pairs a scan with a treatment that targets the same marker. A PET tracer shows which tumours take it up and can help doctors select patients for treatment. A therapeutic radioligand binds the same marker and delivers radiation nearby.

  • PET scan
  • Same tumour marker
  • Targeted radiation

We plan to use our lead binder first as a PET tracer. If it reaches tumours in people, we can assess a version that carries a therapeutic isotope.

Lab evidence

What we’ve seen in the lab

To refine the lead, we compare the activity of successive designs. We use microscopy to check where the labelled binder stains cancer cells.

Normalised dose-response curves for two generations of binders. The second-generation curve is shifted towards lower concentrations.

Activity after optimisation

The second-generation binder reaches a comparable response at a lower concentration.

Patent applications filed for the programme.

Fluorescence micrograph of pancreatic cancer cells showing red binder staining and blue nuclei.

Fluorescence microscopy

Fluorescent binder staining in PANC-1 cells. The binder signal is red and nuclei are blue.

Development plan

From lead optimisation to the first PET study

The next study will track the labelled binder in animals. We’ll use the uptake data to prepare the PET tracer for a first study in people.

Development roadmap

  1. Target selection

    Complete

  2. Hit identification

    Complete

  3. Hit to lead

    Complete

  4. Lead optimisation

    Just started

  5. Preclinical studies

    In vivo tests start in Q1 2027

  6. Phase 0

    Planned

What we plan to measure in Phase 0

Once the safety work and approvals are in place, we plan to give a microdose of labelled binder in a supervised PET study. The scan will show how much reaches tumours, where else it goes and how long it stays. A microdose limits exposure and can reduce the preclinical work needed for the first study. The results will help us decide whether to develop a version that delivers therapeutic radiation. Later trials assess treatment benefit.

FDA guidance on microdose radiopharmaceuticals

Time from target idea to first human data

Conventional ADC path

First-in-human therapeutic study

About 5 years

US$8–11m reported contract range

Fusiomica imaging-first plan

Phase 0 PET uptake data

2–3 years

About €1.2m planned through Phase 0

Planning comparison. The ADC timeline is an illustrative benchmark. The Phase 0 range is our estimate from discovery. The studies answer different questions, and the budgets cover different work.

NIH development timeline · WuXi XDC contract figures (2023)

Why we want human data earlier

Faster design gives us more candidates to work with. A small exploratory study can help us decide which targets are worth taking into larger trials.

Eroom’s law

Drug approvals per inflation-adjusted R&D dollar
Index, 1950 = 100. Illustrative trend based on a halving every nine years.

Historically, the number of drug approvals per billion dollars of R&D spending fell by about half every nine years, after adjusting for inflation. We want to shorten the time between designing a binder and learning where it goes in people.

Scannell et al. on Eroom’s law · What will it take for AI to change drug discovery?

Too many programmes chase the same targets

Programmes in development · reported May 2025
  • PD-1 / PD-L1 · cancer300+
  • GLP-1 · obesity200+
  • CD19150+
  • KRAS150+

Many programmes pursue the same targets. A small Phase 0 PET study can test whether a binder reaches tumours in people and where else it accumulates. Those data reduce uncertainty about delivery before we commit to a larger trial. That makes it easier to assess targets that established drug developers may consider too risky.

Bruce Booth on pipeline crowding · LifeSciVC
Delivery and imaging for ADCs and radioligands
Left, an antibody conjugate releases drug molecules inside a cell. Right, a protein binder carries a radionuclide that emits radiation near the target.

ADC · Releases a drug

Many ADCs enter the cell and release a drug payload after the linker breaks.

A standard ADC gives no signal on PET. Imaging where it accumulates takes a separate radiolabelling study.

RLT · Delivers radiation

A binder carries a radionuclide to the target. Its decay deposits energy in nearby tissue.

A paired PET tracer shows where the binder accumulates in tumours and healthy organs. Repeat scans can track how long it stays.

A radionuclide decays at a known rate. By measuring uptake and retention, we can estimate the radiation dose to tumours and healthy organs. Treatment response is a separate clinical question.

EANM guidance on dosimetry · FDA guidance on ADCs